Evoke Pharma Inc., of Solana Beach, Calif., said it completed patient enrollment in its pivotal phase III study of EVK-001, its nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.